by Elisabeth Kirkeng Andersen | Mar 21, 2023
The platform company Authera, spun out of research at the University of Oslo and Oslo University Hospital, reports that they have entered into a collaborative agreement with one of Europe’s hottest biotechnology companies: argenx. Authera has had a flying start...
by Janncike Kristoffersen | Feb 28, 2023
In 2012, we licensed out technology from the University of Oslo to the Norwegian space technology company Eidel. Now this technology is on its way to the moon! In 2012, we licensed out technology from the University of Oslo to the Norwegian space technology company...
by Janncike Kristoffersen | Jan 16, 2023
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical...
by Elisabeth Kirkeng Andersen | Jan 26, 2022
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by Else Marit Inderberg and Sébastien Wälchli’s research group at the Radium Hospital, Oslo University Hospital. ‘Clinical...
by Elisabeth Kirkeng Andersen | Nov 15, 2021
Inven2 has long experience of licence agreements, particularly in life sciences, which dominate the portfolio. The available licences are presented at all times on our website under ‘Licensing opportunities’. Contact one of our business developers for up-to-date...
by Elisabeth Kirkeng Andersen | Oct 15, 2020
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system. Researchers at the University of Oslo and Oslo University Hospital have recently published an article in the highly reputed...
